IDE a spalla inversa senza stelo INHANCE
Studio randomizzato, prospettico, multicentrico sul sistema di spalla inversa totale senza stelo INHANCE
2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
There is one primary effectiveness endpoint and there are three primary safety endpoints:
-
Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative
-
Primary safety endpoint(s):
- No revision, removal, reoperation, supplemental fixation, or other intervention for any system component
- No humeral or glenoid radiolucent line >2 mm is present in 50% or more zones at 2 years
- No conclusive evidence of migration and tilt (>5mm migration and >10° tilt) of the humeral or glenoid component at 2 years
The study will be successful if the primary effectiveness endpoint non-inferiority analysis is successfully demonstrated, and no significant difference is seen on any of the 3 primary safety endpoints.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Florida
-
Atlantis, Florida, Stati Uniti, 33462
- Orthopedic Center of Palm Beach County
-
-
Massachusetts
-
Waltham, Massachusetts, Stati Uniti, 02451
- Boston Bone & Joint Institute BBJI Formerly BSSC
-
-
Michigan
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Trinity Health Grand Rapids
-
-
Missouri
-
Columbia, Missouri, Stati Uniti, 65201
- Missouri Orthopaedic Institute (MOI)
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28207
- OrthoCarolina Research Institute Charlotte
-
Raleigh, North Carolina, Stati Uniti, 27609
- Duke Orthopaedics of Raleigh
-
-
Ohio
-
Akron, Ohio, Stati Uniti, 44333
- Crystal Clinic Orthopaedic Center
-
Cincinnati, Ohio, Stati Uniti, 45219
- Lindner Research Center
-
Cleveland, Ohio, Stati Uniti, 44195
- The Cleveland Clinic Foundation
-
-
Oregon
-
Eugene, Oregon, Stati Uniti, 97401
- Slocum Center for Orthopaedics and Sports Medicine
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Stati Uniti, 18015
- St. Luke's University Health Network
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Rothman Orthopaedics Institute
-
-
Tennessee
-
Columbia, Tennessee, Stati Uniti, 38401
- MTBJ a division of Tennessee Orthaepedic Alliance
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84108
- University of Utah
-
-
Virginia
-
Fredericksburg, Virginia, Stati Uniti, 22408
- Mary Washington Orthopedics in affiliation with FOA
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Individuals requiring reverse total shoulder replacement for a severely painful, disabling, arthritic joint (i.e. osteoarthritis, post-traumatic arthritis and rotator cuff arthropathy).
- Individuals who are anatomically and structurally suited to receive the implants and have a functional deltoid muscle.
- Individuals who are able to read and comprehend the informed patient consent document and are willing and able to provide informed patient consent for participation in the study and have authorized the transfer of their information to DePuy Synthes.
- Individuals who are willing and able to return for follow-up as specified by the study protocol.
- Individuals who are a minimum age of 22 years at the time of consent.
- Individuals who are willing and able to complete the Patient Reported Outcome Measure questionnaires (PROMs) as specified by the study protocol.
Exclusion Criteria:
- BMI > 40 kg/m2
- Individuals have active, uncontrolled local infection or systemic infection.
- Patients who have not reached skeletal maturity, regardless of age.
- Either preoperatively or intraoperatively and per standard of care medical assessment, bone stock in the proximal humerus or glenoid fossa is determined to be inadequate for supporting the INHANCE humeral stemless components (NOTE: exclusion applies to both arms of the study, i.e., bone stock to be evaluated independent of randomized treatment assignment).
- Intraoperatively and per treating physician's assessment of bone quality, bone is determined to be too soft or porous to support the implant or that is too hard or brittle to allow for proper bone preparation and fixation, i.e. osteoporosis or sclerotic bone, or tumor(s) of the supporting bone structure, where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid.
- Fractures of the proximal humerus that could compromise the fixation of the INHANCE reverse humeral stemless components.
- Patients who have undergone previous treatment on the study shoulder that may compromise fixation of the INHANCE reverse humeral stemless component.
- Revision of a failed hemi, total or reverse shoulder arthroplasty.
- Patient is receiving, or is scheduled to receive, treatment that the Investigator considers could affect bone quality, such as chemotherapy or high dose corticosteroids.
- Individuals who are bedridden per the Investigator's determination.
- Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months.
- Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
- Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have psychological disorders that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
- Patients with a known medical condition that the Investigator believes would impact the study outcomes (including, but not limited to osteomyelitis, Paget's disease, neuropathies such as Charcot's disease, metastatic or neoplastic disorders).
- Patient has a medical condition with less than 2 years life expectancy.
- Patients who are known to be pregnant or breastfeeding.
- Known polyethylene and/or metal sensitivity or allergy.
- Contralateral side has been enrolled in the study or has received a total shoulder operation within the last 6 months
- Otherwise determined by the investigator to be medically unsuitable for participation in this study
- Patient is a member of a vulnerable population (i.e., incarcerated individuals - those incarcerated for at least one month and considered to be an inmate)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: INHANCE Stemless Reverse
INHANCE(TM) Stemless Reverse Total Shoulder |
Uncemented Reverse Total Shoulder |
|
Comparatore attivo: INHANCE Stemmed Reverse
INHANCE(TM) Stemmed Reverse Total Shoulder |
Uncemented Reverse Total Shoulder |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Constant Murley Score (CMS)
Lasso di tempo: Pre-op, 2 years
|
Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score. |
Pre-op, 2 years
|
|
Removal of any system component
Lasso di tempo: 2 year
|
No removal of any system component |
2 year
|
|
Revision of any system component
Lasso di tempo: 2 year
|
No revision of any system component |
2 year
|
|
Reoperation of any system component
Lasso di tempo: 2 year
|
No reoperation of any system component |
2 year
|
|
Supplemental Fixation of any system component
Lasso di tempo: 2 year
|
No supplemental fixation of any system component |
2 year
|
|
Radiolucent Lines (Humeral & Glenoid)
Lasso di tempo: 2 year
|
No humeral or glenoid radiolucent line greater than 2mm is present in 50% or more zones |
2 year
|
|
Migration and Tilt (Humeral & Glenoid)
Lasso di tempo: 2 year
|
No conclusive evidence of migration and tilt (greater than 5mm migration and greater than 10 degrees tilt) of the humeral or glenoid component |
2 year
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Constant Murley Score (CMS)
Lasso di tempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Adjusted Constant-Murley Score at baseline and 3- and 6-months and 1- and 2-years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score. |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
EQ-5D-5L and EQ-VAS
Lasso di tempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
EQ-5D-5L Scores by dimension and EQ-VAS, at baseline and 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Simple Shoulder Test
Lasso di tempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Simple Shoulder Test (SST) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Single Assessment Numeric Evaluation (SANE) Score
Lasso di tempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Single Assessment Numeric Evaluation (SANE) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal". |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Survivorship
Lasso di tempo: 2 year
|
Overall survivorship of the INHANCE Shoulder System at 2 years post-operative, where the system is deemed to be surviving if no components (humeral stem or stemless component, glenosphere, baseplate, liner, etc.) have been removed for any reason, will be presented using the Kaplan-Meier method. |
2 year
|
|
Complications
Lasso di tempo: 2 year
|
The type and frequency of all reportable adverse events (AEs) and device deficiencies in this study will be summarized, with distinction of serious AEs, device and procedure related AEs |
2 year
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Constant Murley Score (CMS)
Lasso di tempo: Pre-op, 3-month, 6-month, 1 year
|
Change from baseline adjusted Constant-Murley Score at 3- and 6-months and 1- year post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score. |
Pre-op, 3-month, 6-month, 1 year
|
|
EQ-5D-5L and EQ-VAS
Lasso di tempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline EQ-5D-5L Value Score and EQ-VAS, at 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Simple Shoulder Test
Lasso di tempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline SST Scores at 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Single Assessment Numeric Evaluation (SANE) Score
Lasso di tempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline SANE Scores at 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal". |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Range of Motion
Lasso di tempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline range of motion at 3- and 6-months and 1- and 2-years post-operative |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- DSM202108
- DSM202108 (Altro identificatore: DePuy Orthopaedics)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .